Navigation Links
UV LED therapy shows promising results in preventing focal seizures
Date:1/6/2010

Researchers from the University of Minnesota Medical School discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. During the study, UV light released gamma aminobutyric acid (GABA) from the "caged" compound carbonyl amino butanoic acid (BC204). GABA then decreased the abnormal electrical activity in the CA1 area of the brain. Results of this study have considerable potential in treating focal epilepsy in humans. Details of this study are available in the January 2010 issue of Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Focal (or partial) epilepsy is very common in both adults and can occur in children. It is caused by an abnormality in a localized area of the brain resulting from such conditions as stroke, trauma, or infections. Up to one-third of epileptic patients fail to respond to conventional medical therapies and are subject to toxic effects from antiepileptic drugs (AEDs). While surgery has benefited some patients with focal epilepsy, a substantial number of patients do not experience a complete remission after operation, prompting researchers to investigate alternative treatments.

Steven Rothman, M.D., and colleagues conducted experiments with UV LEDs to control seizure-like activity in rodent brain slices. Population spikes in CA1 (which reflect the discharge of a population of neurons) were elicited by delivering constant current pulses through a microelectrode placed in the CA3 brain area. Researchers induced seizure-like activity by adding the convulsant, 4-aminopyridine (4-AP; 100 M) and removing magnesium from the fluid solution outside the cells. Caged GABA, BC204, was perfused into the preparation for at least 30 minutes prior to the first illumination.

When population spikes were measured (as a reflection of tissue excitability), the research team found that illumination of control slices with up to 200 mA LED current had no effect on peak amplitudes. Addition of BC204 (30 M) and illumination using as little as 50 mA LED current produced a statistically significant reduction of the peak of the population spike. More important, BC204 (10 M) significantly reduced the slice spikes and bursting induced by the 4-AP and low magnesium.

"Our strongly positive results, in an epilepsy model far more severe than the naturally occurring disease, suggest that this technique could translate to human epilepsy," said Dr. Rothman. Researchers believe that a programmable pump could deliver the caged GABA into the subarachnoid space over the epileptic area of the brain. UV LEDs could then be responsively activated to release GABA, using techniques similar to those used for cortical stimulation units that are currently in clinical trials.

The researchers are optimistic that an LED-based implantable device is feasible. "Optical stimulation would be a far more rapid delivery method than any mechanical device for direct administration of drug into the brain and would not subject patients to toxic doses of medication or irreversible brain damage from epilepsy resections," concluded Dr. Rothman.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Sexual function does not continuously decline after radiation therapy treatments for prostate cancer
2. Ring in a Healthy New Year with Massage Therapy in 2010
3. Lithium Beats Valproate for Long-Term Bipolar Therapy
4. Gene Therapy Holds Promise for Emphysema
5. Researchers discover gene therapy to prevent progression of emphysema
6. Psychotherapy offers obesity prevention for at risk teenage girls
7. Rockville and Gaithersburg Now Has Spinal Decompression Therapy
8. HIV Therapy Linked to Fewer Suicides
9. Study finds racial disparities exist in radiation therapy rates for early stage breast cancer
10. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
11. Targeted therapy prolongs life in patients with HER2-positive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, ... today that Legacy Health is expanding its use of Intrigma’s cloud-based physician scheduling ... successful initial proof of concept. The Portland, Oregon based health system conducted a ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... a special type of surgical procedure that can be used to diagnose and treat ... instruments can be inserted. These instruments include a special lighting system and lens that ...
(Date:5/3/2016)... ... , ... Finding the right way to address a patient’s condition before it worsens will ultimately ... board. , “You do the right thing, at the right time, at the right dose ... said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if the cost of ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Dave Newberry, broker/owner ... Interim Care Center (PICC) annual fundraiser luncheon on Friday, May 20. “We have ... the smallest victims of drug abuse,” said Newberry. , PICC is a local Kent, ...
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been announced ... for five events throughout the month of May. , Uldrich is the author of ... outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery Channel’s Inside ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... Dr. Vivek Ahuja , George ... phen Schmidt Join the Growing Organization ... for life sciences, today announced key new leaders have joined the ... a growing business.  This will bolster the company,s safety business unit ... ArisGlobal in the position of Vice President - Safety. George has ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
Breaking Medicine Technology: